蜂针对原发性肝癌患者镇痛作用的临床观察
|
摘要
目的：
本研究采用蜂针结合镇痛药对原发性肝癌疼痛患者进行治疗,观察蜂针在原发性肝癌疼痛患者中所起的作用,也为临床治疗提供一种更为安全有效的治疗方法。
方法：
所有60例病人均来源于广州中医药大学—附院肿瘤科及针灸门诊,采用随机数字表法将符合纳入标准的病例随机分为治疗组和对照组,每组30例。治疗组为镇痛药配合蜂针治疗。对照组仅予镇痛药治疗。三个疗程结束后观察疗效。治疗前予测量卡氏评分(KPS)、体力状况评分(PS)以选择纳入病例；分别在治疗前及疗程结束后测取患者的红细胞(RBC)、白细胞(WBC)、血小板(PLT)、谷丙转氨酶(ALT)、谷草转氨酶(AST).HBV-DNA；分别于治疗前和疗程结束后进行汉密尔顿抑郁量表评分(HAMD);分别于治疗前、疗程结束后、疗程结束后24小时进行视觉模拟评分(VAS),并观察治疗前后数据的变化。所有数据均采用SPSS17.0进行统计分析。
结果：
(1)治疗组和对照组三个疗程结束时总疗效比较,P>0.05,差异无统计学意义,提示此时两组总疗效基本一致；治疗组和对照组治疗结束24h总疗效比较,P<0.05,差异有统计学意义,提示疗程结束后24h,治疗组疗效要好于对照组。
(2)VAS评分比较,先行重复测量设计的方差分析,经球形检验,P=0.933,P>0.05,不拒绝球形假设,对上述资料行单变量方差分析。主体间效应的检验,P<0.05,差异有统计学意义；主体内效应的比较, P<0.05,差异有统计学意义,提示治疗组疼痛情况比对照组更有改善。
(3)治疗组与对照组平均镇痛起效时间比较, P>0.05,差异无统计学意义,提示两组镇痛起效时间方面无显著差异；两组镇痛维持时间比较, P<0.05,差异有统计学意义,提示治疗组镇痛维持时间要长于对照组。
(4)HAMD评分比较,治疗组与对照组治疗前比较P>0.05,提示二者具有可比性；两组治疗后比较,P<0.05,差异有统计学意义,提示治疗后治疗组抑郁程度比对照组为轻；治疗组治疗前后比较,P<0.05,差异有统计学意义,提示治疗组治疗后抑郁程度比治疗前为轻；对照组治疗前后比较, P>0.05,差异无统计学意义,提示对照组治疗前后患者抑郁程度无明显变化。
(5)治疗组和对照组治疗前红细胞比较, P>0.05,说明两组有可比性；治疗后两组红细胞比较, P>0.05,差异无统计学意义,说明治疗后治疗组和对照组红细胞无显著差异；治疗组治疗前与治疗后比较,P>0.05,差异无统计学意义,说明治疗组治疗前后红细胞无明显变化；对照组治疗前与治疗后比较P>0.05,差异无统计学意义,说明对照组治疗前后红细胞无明显变化。
(6)治疗组与对照组治疗前血小板比较, P>0.05,说明二者具有可比性；治疗后两组血小板比较, P<0.05,差异有统计学意义,说明治疗后治疗组比对照组血小板增加明显；治疗组治疗前后比较, P<0.05,差异有统计学意义,提示治疗组治疗后血小板比治疗前为高；对照组治疗前后比较P>0.05,差异无统计学意义,提示对照组治疗前后血小板无明显变化。
(7)治疗组与对照组治疗前白细胞比较, P>0.05,说明二者具有可比性；治疗后两组比较, P<0.05,差异有统计学意义,提示治疗后治疗组比对照组白细胞增加明显；治疗组治疗前后比较, P<0.05,差异有统计学意义,提示治疗组治疗后白细胞比治疗前为高；对照组治疗前后比较, P>0.05,差异无统计学意义,说明对照组治疗前后白细胞无明显变化。
(8)治疗组与对照组治疗前谷草转氨酶比较,P>0.05,说明二者具有可比性；治疗组与对照组治疗后比较,P<0.05,差异有统计学意义,提示治疗后治疗组谷草转氨酶比对照组降低明显；治疗组治疗前后比较, P<0.05,差异有统计学意义,说明治疗组治疗后谷草转氨酶比治疗前为低；对照组治疗前后比较,P>0.05,差异无统计学意义,说明对照组治疗前后谷草转氨酶无明显变化。
(9)治疗组与对照组治疗前谷丙转氨酶比较, P>0.05,说明二者具有可比性；治疗组和对照组治疗后比较, P<0.05,差异有统计学意义,提示治疗后治疗组谷丙转氨酶比对照组降低明显；治疗组治疗前与治疗后比较, P<0.05,差异有统计学意义,说明治疗组治疗后谷丙转氨酶比治疗前低；对照组治疗前与治疗后比较,P>0.05,差异无统计学意义,说明对照组治疗前后谷丙转氨酶无明显变化。
(10)治疗组和对照组治疗前HBV-DNA比较,P>0.05,提示二者具有可比性。治疗组和对照组治疗后比较,P<0.05,差异有统计学意义,说明治疗后治疗组HBV-DNA载量比对照组降低明显；治疗组治疗前后比较,P<0.05,差异有统计学意义,说明治疗组治疗后HBV-DNA载量比治疗前降低；对照组治疗前后比较, P>0.05,差异无统计学意义,说明对照组治疗前后HBV-DNA无明显变化。
结论：
1.两种治疗方法对原发性肝癌疼痛均有一定的疗效。
2.镇痛药配合蜂针组对原发性肝癌疼痛的控制要好于单纯镇痛药组,而且前者能显著缓解患者的抑郁状态。
3.镇痛药配合蜂针组治疗能显著升高白细胞、血小板的值,在调节免疫方面要好于单纯镇痛药组；镇痛药配合蜂针组能降低患者谷草转氨酶、谷丙转氨酶值,并能降低患者HBV-DNA载量,提示镇痛药配合蜂针组在抑制病毒复制、保护肝细胞方面要好于单纯镇痛药组。
Objective
This study used apitherapy and analgesics in patients who suffered from primary liver cancer, and observed apitherapy's role in patients with primary liver cancer pain, and provided a more safe and effective clinical treatment.
Methods
All60patients from the first Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, were divided into treatment group and control group,30cases in each group. Then we observed Karnofsky (KPS), Performance Status (PS), red blood cells (RBC), white blood cells (WBC), platelet (PLT), alanine aminotransferase (ALT), aspertate aminotransferase (AST), HBV-DNA, Hamilton Depression Scale (HAMD), visual analog scale (VAS), and so on. All data were analyzed by SPSS17.0.
Results
(1) There was no significant difference in curative effect after three courses between treatment group and control group (P>0.05) while there was a significant difference in curative effect after24h of three courses (P<0.05).
(2) There was a significant difference in visual analog scale between treatment group and control group(P<0.05).
(3) There was no significant difference in the onset time of analgesia between treatment group and control group (P>0.05) while there was a significant difference in Duration of analgesia between treatment group and control group (P<0.05).
(4) There was no significant difference in Hamilton Depression Scale before treatment between treatment group and control group (P>0.05) while there was a significant difference in Hamilton Depression Scale after treatment between treatment group and control group (P<0.05).
(5) There was no significant difference in RBC before treatment between treatment group and control group (P>0.05), and there was no significant difference in RBC after treatment between treatment group and control group (P>0.05).
(6) There was no significant difference in PIT before treatment between treatment group and control group (P>0.05) while there was a significant difference in PLT after treatment between treatment group and control group (P<0.05).
(7) There was no significant difference in WBC before treatment between treatment group and control group (P>0.05) while there was a significant difference in WBC after treatment between treatment group and control group (P<0.05).
(8) There was no significant difference in AST before treatment between treatment group and control group (P>0.05) while there was a significant difference in AST after treatment between treatment group and control group (P<0.05).
(9) There was no significant difference in ALT before treatment between treatment group and control group (P>0.05) while there was a significant difference in ALT after treatment between treatment group and control group (P<0.05).
(10) There was no significant difference in HBV-DNA before treatment between treatment group and control group (P>0.05) while there was a significant difference in HBV-DNA after treatment between treatment group and control group (P<0.05).
Conclusion
1.The two methods of treatment to primary liver cancer all have certain curative effect.
2. The effect of analgesics with apitherapy group for primary liver cancer pain is better than simple analgesics group, and the former can significantly relieve the depressive state of patients.
3. Analgesics with apitherapy treatment group can significantly improve WBC, PLT, ALT, AST, HBV-DNA while simple analgesics group havs no effect on those sides.
本研究采用蜂针结合镇痛药对原发性肝癌疼痛患者进行治疗,观察蜂针在原发性肝癌疼痛患者中所起的作用,也为临床治疗提供一种更为安全有效的治疗方法。
方法：
所有60例病人均来源于广州中医药大学—附院肿瘤科及针灸门诊,采用随机数字表法将符合纳入标准的病例随机分为治疗组和对照组,每组30例。治疗组为镇痛药配合蜂针治疗。对照组仅予镇痛药治疗。三个疗程结束后观察疗效。治疗前予测量卡氏评分(KPS)、体力状况评分(PS)以选择纳入病例；分别在治疗前及疗程结束后测取患者的红细胞(RBC)、白细胞(WBC)、血小板(PLT)、谷丙转氨酶(ALT)、谷草转氨酶(AST).HBV-DNA；分别于治疗前和疗程结束后进行汉密尔顿抑郁量表评分(HAMD);分别于治疗前、疗程结束后、疗程结束后24小时进行视觉模拟评分(VAS),并观察治疗前后数据的变化。所有数据均采用SPSS17.0进行统计分析。
结果：
(1)治疗组和对照组三个疗程结束时总疗效比较,P>0.05,差异无统计学意义,提示此时两组总疗效基本一致；治疗组和对照组治疗结束24h总疗效比较,P<0.05,差异有统计学意义,提示疗程结束后24h,治疗组疗效要好于对照组。
(2)VAS评分比较,先行重复测量设计的方差分析,经球形检验,P=0.933,P>0.05,不拒绝球形假设,对上述资料行单变量方差分析。主体间效应的检验,P<0.05,差异有统计学意义；主体内效应的比较, P<0.05,差异有统计学意义,提示治疗组疼痛情况比对照组更有改善。
(3)治疗组与对照组平均镇痛起效时间比较, P>0.05,差异无统计学意义,提示两组镇痛起效时间方面无显著差异；两组镇痛维持时间比较, P<0.05,差异有统计学意义,提示治疗组镇痛维持时间要长于对照组。
(4)HAMD评分比较,治疗组与对照组治疗前比较P>0.05,提示二者具有可比性；两组治疗后比较,P<0.05,差异有统计学意义,提示治疗后治疗组抑郁程度比对照组为轻；治疗组治疗前后比较,P<0.05,差异有统计学意义,提示治疗组治疗后抑郁程度比治疗前为轻；对照组治疗前后比较, P>0.05,差异无统计学意义,提示对照组治疗前后患者抑郁程度无明显变化。
(5)治疗组和对照组治疗前红细胞比较, P>0.05,说明两组有可比性；治疗后两组红细胞比较, P>0.05,差异无统计学意义,说明治疗后治疗组和对照组红细胞无显著差异；治疗组治疗前与治疗后比较,P>0.05,差异无统计学意义,说明治疗组治疗前后红细胞无明显变化；对照组治疗前与治疗后比较P>0.05,差异无统计学意义,说明对照组治疗前后红细胞无明显变化。
(6)治疗组与对照组治疗前血小板比较, P>0.05,说明二者具有可比性；治疗后两组血小板比较, P<0.05,差异有统计学意义,说明治疗后治疗组比对照组血小板增加明显；治疗组治疗前后比较, P<0.05,差异有统计学意义,提示治疗组治疗后血小板比治疗前为高；对照组治疗前后比较P>0.05,差异无统计学意义,提示对照组治疗前后血小板无明显变化。
(7)治疗组与对照组治疗前白细胞比较, P>0.05,说明二者具有可比性；治疗后两组比较, P<0.05,差异有统计学意义,提示治疗后治疗组比对照组白细胞增加明显；治疗组治疗前后比较, P<0.05,差异有统计学意义,提示治疗组治疗后白细胞比治疗前为高；对照组治疗前后比较, P>0.05,差异无统计学意义,说明对照组治疗前后白细胞无明显变化。
(8)治疗组与对照组治疗前谷草转氨酶比较,P>0.05,说明二者具有可比性；治疗组与对照组治疗后比较,P<0.05,差异有统计学意义,提示治疗后治疗组谷草转氨酶比对照组降低明显；治疗组治疗前后比较, P<0.05,差异有统计学意义,说明治疗组治疗后谷草转氨酶比治疗前为低；对照组治疗前后比较,P>0.05,差异无统计学意义,说明对照组治疗前后谷草转氨酶无明显变化。
(9)治疗组与对照组治疗前谷丙转氨酶比较, P>0.05,说明二者具有可比性；治疗组和对照组治疗后比较, P<0.05,差异有统计学意义,提示治疗后治疗组谷丙转氨酶比对照组降低明显；治疗组治疗前与治疗后比较, P<0.05,差异有统计学意义,说明治疗组治疗后谷丙转氨酶比治疗前低；对照组治疗前与治疗后比较,P>0.05,差异无统计学意义,说明对照组治疗前后谷丙转氨酶无明显变化。
(10)治疗组和对照组治疗前HBV-DNA比较,P>0.05,提示二者具有可比性。治疗组和对照组治疗后比较,P<0.05,差异有统计学意义,说明治疗后治疗组HBV-DNA载量比对照组降低明显；治疗组治疗前后比较,P<0.05,差异有统计学意义,说明治疗组治疗后HBV-DNA载量比治疗前降低；对照组治疗前后比较, P>0.05,差异无统计学意义,说明对照组治疗前后HBV-DNA无明显变化。
结论：
1.两种治疗方法对原发性肝癌疼痛均有一定的疗效。
2.镇痛药配合蜂针组对原发性肝癌疼痛的控制要好于单纯镇痛药组,而且前者能显著缓解患者的抑郁状态。
3.镇痛药配合蜂针组治疗能显著升高白细胞、血小板的值,在调节免疫方面要好于单纯镇痛药组；镇痛药配合蜂针组能降低患者谷草转氨酶、谷丙转氨酶值,并能降低患者HBV-DNA载量,提示镇痛药配合蜂针组在抑制病毒复制、保护肝细胞方面要好于单纯镇痛药组。
Objective
This study used apitherapy and analgesics in patients who suffered from primary liver cancer, and observed apitherapy's role in patients with primary liver cancer pain, and provided a more safe and effective clinical treatment.
Methods
All60patients from the first Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, were divided into treatment group and control group,30cases in each group. Then we observed Karnofsky (KPS), Performance Status (PS), red blood cells (RBC), white blood cells (WBC), platelet (PLT), alanine aminotransferase (ALT), aspertate aminotransferase (AST), HBV-DNA, Hamilton Depression Scale (HAMD), visual analog scale (VAS), and so on. All data were analyzed by SPSS17.0.
Results
(1) There was no significant difference in curative effect after three courses between treatment group and control group (P>0.05) while there was a significant difference in curative effect after24h of three courses (P<0.05).
(2) There was a significant difference in visual analog scale between treatment group and control group(P<0.05).
(3) There was no significant difference in the onset time of analgesia between treatment group and control group (P>0.05) while there was a significant difference in Duration of analgesia between treatment group and control group (P<0.05).
(4) There was no significant difference in Hamilton Depression Scale before treatment between treatment group and control group (P>0.05) while there was a significant difference in Hamilton Depression Scale after treatment between treatment group and control group (P<0.05).
(5) There was no significant difference in RBC before treatment between treatment group and control group (P>0.05), and there was no significant difference in RBC after treatment between treatment group and control group (P>0.05).
(6) There was no significant difference in PIT before treatment between treatment group and control group (P>0.05) while there was a significant difference in PLT after treatment between treatment group and control group (P<0.05).
(7) There was no significant difference in WBC before treatment between treatment group and control group (P>0.05) while there was a significant difference in WBC after treatment between treatment group and control group (P<0.05).
(8) There was no significant difference in AST before treatment between treatment group and control group (P>0.05) while there was a significant difference in AST after treatment between treatment group and control group (P<0.05).
(9) There was no significant difference in ALT before treatment between treatment group and control group (P>0.05) while there was a significant difference in ALT after treatment between treatment group and control group (P<0.05).
(10) There was no significant difference in HBV-DNA before treatment between treatment group and control group (P>0.05) while there was a significant difference in HBV-DNA after treatment between treatment group and control group (P<0.05).
Conclusion
1.The two methods of treatment to primary liver cancer all have certain curative effect.
2. The effect of analgesics with apitherapy group for primary liver cancer pain is better than simple analgesics group, and the former can significantly relieve the depressive state of patients.
3. Analgesics with apitherapy treatment group can significantly improve WBC, PLT, ALT, AST, HBV-DNA while simple analgesics group havs no effect on those sides.
引文
[1]陈孝平.肝胆外科学.第1版,北京：人民卫生出版社,2005：449.
[2]赵永飞,王贵吉,裴迎新,等.肝癌患者生活方式与饮食危险因素调查河南医学研究,2012,21(4)：471-474.
[3]王清云肝癌与情志关系[J].吉林中医药,2004,24(8)：47
[4]胡学军,龙顺钦,杨小兵,等.原发性肝癌的中医体质调查分析[J].时珍国医国药,2010,21(4)：995-996.
[5]侯炜,梁婷,周雍明.原发性肝癌的中医药临床研究进展[J].肿瘤学杂志,2010,16(7)：534-536.
[6]孙秉严.癌症的治疗与预防[M].北京：春秋出版社,1988：3.
[7]刘亚娴.中西医结合肿瘤病学[M].北京：中国中医药出版社,2005.
[8]杨通礼.中医药治疗肝癌基本原则和方药初探[J].中国中医药导报,1996,11(6)：42-45.
[9]王天保,范言磊.辨证施治原发性肝癌153例[J].中医研究,1999,12(6)：46～47.
[10]张尚忠.对肝癌辨证施治的认识[J].山东中医学院学报,1978,(增刊)：178～179.
[11]韩克起,邱根全,孙喜才.肝癌发热证治六法[J].陕西中医,1996,17(7)：307-308.
[12]周维顺,谢长生.略论肝癌的诊治原则[J].浙江中医学院学报,1993,17(6)：4-5.
[13]谭开基,陈锐深.岭南肝癌的发病特点及辨证施治[J].新中医,1999,31(8)：25.
[14]刘庆,张彦博,马传红,等.原发性肝癌的中医治法与方药[J].中西医结合学报,2005,3(4)：260-262.
[15]高晓红.辨证治疗原发性肝癌28例[J].湖南中医杂志,2002,18(5)：27.
[16]陈洪国,杜晓军.内外合治中晚期肝癌30例山西中医,2005,21(5)：15.
[17]黄金昶,崔慧娟,王立森,等.养阴活血、温阳利水法为主治疗门静脉癌栓10例[J].中日友好医院学报,2005,19(2)：111-112.
[18]邵世祥,王子鑫,毕磊.五倍子散配合华蟾素注射液治疗原发性肝癌51例[J].实用中医内科杂志,2006,20(1)：93.
[19]田菲,贾英杰,陈军,等.温针灸对于恶性肿瘤患者的免疫微生物调控[J].针灸临床杂志,1999,15(5)：48-50.
[20]刘宏.针灸与穴位注射药物治疗肝癌疼痛疗效研究[J].河北中医药学报,2010,25(3)：37.
[21]刘立公,顾杰.癥瘕积聚的古代针灸治疗特点分析[J].针灸临床杂志,2004；20(2)：57.
[22]何秀兰,乔占兵,李忠.中医治肝癌评述[J].光明中医,2002；17(4)：37-39.
[23]丁正荣,李荣成,黄果勇,等.原发性肝癌与乙型肝炎病毒病因关系的流行病学分析与探讨
[J].中华流行病学杂志,1984,5(6)：146-149.
[24]丁正荣,李荣成,龚健,等.肝癌高发区HBsAg携带者及肝脏损害者发生肝癌的前瞻性研究[J].肝炎防治研究,1985,6(4)：22-30.
[25]Hsieh YH, SU IJ, Wang HC, et al. Pre-s mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage [J]. Carcinogenesis,2004,25 (10):2023.
[26]向光明,钟森,赵川,等.HBV相关肝细胞癌患者HBV前S／S基因变异的分析[J].泸州医学院学报,2006,29(5)：410-413.
[27]Wang XW, Forrester K, Yeh H, et al. Hepatitis B virus X protein inhibits p53 sequence-specific DNAbinding, transcriptional activity, and association with transcription factor ERCC3 (J). Proc Natl Acad Sci USA,1994,91:2230-2234.
[28]Webber EM,Wu JC, Wang L, et al. Overexpression of transforming growth factor-alphacauses liver enlargement and increased hepatocyte proliferation in transgenic mice (J). AmJ Pathol,1994,145:398-408.
[29]BATTAGLIA S, BENZOUBIR N, NOBILET S, et al. Liver cancer-derived hepatitis C virus core proteins shift TGF-β responses from tumor suppression to epithelial-mesenchymal transition[J]. PLoS One,2009,4:e4355.
[30]曾蓉,李秀玲,余蓉.蛇毒抗肿瘤作用研究进展[J].生物技术通讯,2002；13(6)：479-483.
[31]Simmonds P. Variability of hepatitis C virus [J]. Hepatology 1995,21(2):570—583.
[32]Gramantieri L, Trere D, Pession A, et al. Allelic imbalance on 16q in small, unifocal hepatocellular carcinoma:correlation with HBV and HCV infections and cellular proliferation rate[J].Dig, Dis Sci,2000,45(2):306—311.
[33]Tornillo L, Carafa V, Richter J, et al. Marked genetic Similari-ties between hepatitis B virus-positive and hepatitis C virus-positive hepatocellular carcinomas [J]. J Pathol, 2000,192(3):307-312.
[34]Ogata S, Ku Y, Yoon S, et,al.Correlation between secondary structure of an amino-terminal portion of the nonstructural protein 3 (NS3) of hepatitis C virus and development of hepa-tocellular carcinoma[J]. Microbiol Immunol,2002,46(8):549-554.
[35]Ray RB, Steele R, Meyer K, et al.J Bio Chem,1997; 272(17):10983-10986
[36]张文萍.蝎毒抗癌多肽的研究进展[J].中草药,2002；33(12)：1143-1145.
[37]李艳荣,刘云鹏.蟾蜍毒素的抗肿瘤作用.国外医学中医中药分册[J],2002；24(3)：152-155.
[38]陆再英,钟南山.内科学[M]. 北京：人民卫生出版社,2008：457-462.
[39]Lencioni R, Bartolozzi C, Caramella D, et al. Treatment of small hepatocellular carcinoma with percutaneous ethanol injection-analysis of prognostic factors in 105 western patients. Cancer,1995,76:1737.
[40]蔡鹏,孙劲松,杨士勇.全身γ刀治疗52例原发性肝癌近期疗效观察.中国肿瘤临床与康复,2002,9(5)：97.
[41]Sakon M, Nagano H, Dono K, et al. Combined intraarial 5—fluorouracil and subcutaneous interferon — alphatherapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer,2000,94:435—442.
[42]FENNELL JF, SHIPMAN WH, COLE LJ. Antibacterial action of a bee venom fraction (melittin) against a penicillin-resistant staphylococcus and other microorganisms[J]. Res Dev Tech Rep,1967:1-13.
[43]刘红云,童富淡. 蜂毒的研究进展及其临床应用[J]. 中药材,2003,26(6)：456-458.
[44]彭辉,张志芳. 蜂针联合三阶梯止痛疗法治疗癌痛的临床观察[J].湖南中医药大学学报,2010,30(9)：222-225.
[45]杨毓麟,姚珠姮,俞宗耀,等.蜂毒的镇痛作用——与吗啡、安替比林的比较[J].中国养 蜂,1984,(2)：26-27.
[46]Kubo H, Loegering DA, Adolphson CR, et al. Cytotoxic properties of eosinophil granule major basic protein for tumor cells [J]. Int Arch Allergy Immunol,1999; 118(2-4):426-428.
[47]Saini S S, Chopra A K, Peterson JW. Melittin activates endogenous phospholipase D during cytolysis of human monocytic leukemia cells[J]. Toxicon,1999,37(11):1605.
[48]张晨,凌昌全,李柏,等.蜂毒素对肝癌细胞系SMMC7721增殖的影响[J].中草药,2003,34(1)：43-45.
[49]KuboH, LoegeringD A, Adolphson C R, et a.1 Cytotoxic properties of eosinophil granulemajorbasic protein for tumor cells[J]. IntArch A-llergy Immuno,11999,118(2-4): 426.
[50]LazarevV N, Parfenova TM, Gularyan SK, et a.1 Induced expression of melittin, an antimicrobial peptide, inhibits infection by Chlamydia tra-chomatis andMycoplasma hominis in aHela cell line[J]. IntJAntim-icrob Agents,2002,19(2):133.
[51]Werkmeister JA, Kirkpatrick A, McKenzie JA, et al. The effect of sequence variations and structure on the cytolytic activity of melittin peptides[J]. Biochim Biophys Acta,1993,1157(1):50.
[52]Dunn RD,Weston KM, Longhurst TJ,et al. Antigen binding and cytotoxic properties of a recombinant immunotoxin incorpo-rating the lytic peptide[J]. Melittin Immunotechnology,1996,2(3):229.
[53]李爱剑,梁枫.蜂毒素对人胃癌细胞BGC823生长抑制作用的实验研究[J].中国中医急症,2009,18(5)：780.
[54]Harada M, Kimura G, Nomoto K. Heat shock proteins and the antitumor T cell response[J]. Biotherapy,1998,10 (3):229.
[55]王秋波,鲁迎年,臧云娟,等，蜂毒的免疫调节机制研究[J].中国免疫学杂志,2000,16(10)：542-544.
[56]高连臣.蜂毒对T淋巴细胞亚群的影响[J].养蜂科技,2004,23(3)：29-30.
[57]朱萱萱,王居祥,王瑞平,等.蜂毒对S180肉瘤鼠的免疫调节作用[J].中药药理与临床,2000,16(6)：24-25.
[58]黄雪强,凌昌全,陈哲,等.蜂毒素诱导人T淋巴细胞白血病细胞株6T-CEM的凋亡作用[J].安徽中医学院学报,2001；20(5)：39-41.
[59]Williams GT, Smith CA. Molecular regulation of apoptosis:genetic controls on cell death. Cell,1993,74 (5):777.
[60]周语平,杨志军,陈彻.细胞凋亡与肿瘤[J].甘肃中医学院学报,2003,20(4)：48-51.
[61]李玉梅,陈永强,顾伟.蜂毒及其主要成分蜂毒素抗肿瘤机制研究进展[J].中国中医药信息杂志,2008,15(1)：96-97.
[62]张晨,李柏,吕书勤,等.蜂毒素对人肝癌细胞线粒体膜蛋白7A6和凋亡相关基因产物Fas及其配体FasL表达的影响.中西医结合学报,2007,5(5)：559.
[63]Jang MH, Shin MC, Lim S, et al. Bee venom induces apoptosis and inhibits expression of cyclooxygenase-2 mRNA in human lung cancer cell line NCI-H1299[J]. J Parmacol Sci,2003,91: 95-104.
[64]Hwang DY, Kim HH, Kim CJ, et al. Bee venom induces apoptosis and inhibits COX-2 in human osteosarcoma cell line MG-63[J]. J Kor Acup Mox Soc,2003,20(3):63—74.
[65]Ahn CB, Im CW, Kim CH, et al. Apoptotic cell death by melittin through induction of Bax and activation of caspase proteases in human lung carcinoma cells[J]. J Kor Acup Mox Soc,2004,21(2):41-55.
[66]吴围屏,刘自元,孟令,等.蜂毒体外抗凝和降粘作用初探蜜蜂杂志,1999,(6)：3-4.
[67]徐彭,欧阳永伟,肖诚.蜂毒活血化痪作用的实验观察[J].中草药,1996,27(9)：542-543.
[68]游育红,邬大元,黄自强.蜂毒素对大鼠血小板内钙浓度的影响[J].福建医学院学报,1995,29(4)：347-348.
[69]陈远聪,袁士龙.毒素的研究和利用[M].科学出版社,1988年第1版：128-144.
[70]郭芳彬.蜂毒的现代药理研究[J].养蜂科技,2003,(2)：29-31.
[71]李惠敏,张苏刚,魏振满,等.复方蜂毒注射液对大鼠实验性肝纤维化的治疗作用[J].中国生化药物杂志,1998,19(1)：25-26.
[72]马爱生.以毒攻毒德研究用蜂毒对付艾滋病[J].蜜蜂杂志,2000,(2)：30.
[73]王强,王庆友.病毒性肝炎蜂毒抗病毒疗效分析[J].蜜蜂杂志,2003,9：4-5.
[74]张秀兰.蜂毒注射液治疗白塞病[J].中华皮肤科杂志,1997,30(1)：55.
[75]Chen J, et allThe contribution of spinal neuronal changes to development of prolonged, tonic nociceptive responese of the cat induced by subcutaneous bee venom injectionl Eur J Pain,1998,2 (4):359.
[76]Luo C, et allSpatial and temporal expression of c-Pos protein in the spinal cord of anesthetized rat induced by subcutaneous bee venom injectionlBrain Res, 1998,806 (2):175.
[77]李万瑶,涂成文,黄胜光.蜂针对类风湿性关节炎作用机理的研究[J].广东省针灸学会第十次学术交流会论文汇编[C].广东广州,2007.
[78]韩巧菊,于丽华,陈淑兰,等.蜂针、蜡疗及蜂产品和中药内服治疗早、中期强直性脊柱炎240例临床观察[J].河北中医,2010,32(8)：1213-1214.
[79]朱辉军,黄胜光,谭宁,等.蜂针合补肾化瘀方治疗强直性脊柱炎56例[J].中医药导报,2009，15(9)：33-34.
[80]王小寅.蜂针联合推拿治疗神经根型颈椎病50例疗效分析[J].中医临床杂志,2012,4(6)：44-45.
[81]沈明安.蜂针配合推拿治疗肩周炎临床观察[J].四川中医,2008,26(4)：117-118.
[82]黄海振,陈希,张还添,等.蜂针配合中药内服治疗膝骨性关节炎[J].光明中医,2008,23(9)：1273-1274.
[83]臧云娟, 王秋波,于海青,等.独穴蜂针疗法对变应性鼻炎防治效果的观察与分析[J].蜜蜂杂志,1999,(7)：3-4.
[84]文洁珍.蜂针治疗儿童哮喘的临床疗效及对免疫功能的影响[J].新中医,2006,38(7)：37-38.
[85]成永明,任小红,富永谦,等.蜂疗防治小儿反复呼吸道感染的临床研究[J].中医药导报,2005,11(9)：10-11.
[86]王太发.蜂针针刺穴位治疗面神经麻痹38例疗效观察光明中医,2010,25(4)：650.
[87]唐金贤,李素英.蜂针治疗96例原发性三叉神经痛[J].养蜂科技,1995,(3)：21-22.
[88]谭保华,王苏娜.蜂针蜇刺法治疗顽固性面瘫36例疗效观察[J].云南中医中药杂志,2012,33(1)：50.
[89]韩励兵,王苏娜,段晓荣,等.蜂针治疗脑梗塞50例疗效观察[J].云南中医中药杂志,2011,32(3)：43.
[90]陈景秀.超量蜂针治疗格林-巴利综合征7例[J].养蜂科技,2004,(3)：31-33.
[91]廖子俊,朱万云.足三里穴在蜂针治疗消化系统病症中的应用[J].中国蜂业,2009,60(6)：37-38.
[92]苏和祖,聂承和,陈玉钦.蜂针疗法治疗肝硬化32例疗效观察[J].蜜蜂杂志,1994,(9)：5-7.
[93]代乾.蜂胶酊中药合剂与蜂针综合治疗慢性喉炎[J].中国蜂业,2011,62(4)：34.
[94]朱金明.蜂疗为何能帮助阑尾炎患者保留阑尾[J].2006,(6)：26-28.
[95]成永明,任小红,余伯亮.蜂疗治疗小儿遗尿症60例[J].实用医学杂志,2009,25(16)：2777.
[96]周福环,周福锁.蜂针配合毫针治疗乳腺增生127例临床观察[J].中国养蜂,2005,56(2)：28.
[97]吴新新.蜂针治疗功能性痛经10例[J].蜜蜂杂志,2006,(2)：32.
[98]代乾.地归敷贴与蜂针治疗更年期综合症[J].中国蜂业,2008,59(5)：33.
[99]廖子俊,朱万云.慢性前列腺炎的临床症状及蜂针疗法[J].中国蜂业,2009,60(1)：36-37.
[100]廖子俊,朱万云.痤疮蜂针疗法[J].中国蜂业,2009,60(12)：42-43.
[101]代乾.蜂针和复方蜂胶液治疗湿疹104例效果分析[J].养蜂科技,2004(3)：34-35.
[102]石桂华,郑建寅,罗铁阳.蜂针配合矿泉浴治疗关节型银屑病[J].中华皮肤科杂志,1997，30(5)：346-347.
[103]廖子俊,朱万云.银屑病的临床症状及蜂针疗法[J].中国蜂业,2009,60(5)：31-32.
[104]耿振方,马中梅.蜂针治愈体表血管瘤、皮肤纤维瘤85例[J].养蜂科技,2004,(6)：30.
[105]葛来安,彭莉莉,杨保东.蜂针联合中药治疗晚期肝癌的临床体会[J].江西中医药,2009，40(11)：36-37.
[106]王居祥,朱超林,王瑞平,等.蜂毒注射液治疗恶性肿瘤的临床观察[J].南京中医药大学学报,2006,22(3)：157-159.
[107]彭莉莉,葛来安,严景妍,等.中药联合蜂针辨证治疗慢性乙型肝炎50例临床观察[J].辽宁中医杂志,2010,37(12)：2373-2375.
[108]刘文清,吴汉周.蜂毒治疗慢性乙型肝炎与肝硬化32例[J].中西医结合肝病杂志,1993,3,(4)：31-32.
[109]杨文超,戴荣国,吴珍红,等.蜂毒肽抗HSV-1病毒作用的机理研究[J].中国蜂业,2010,61(12)： 35-36.
[110]陈世云,熊俊,李万瑶.近30年蜂针疗法病症谱的文献研究[J].广州中医药大学学报,2012,29(6)：733-735.
[111]刘厚钰.原发性肝癌[M].北京：人民卫生出版社,2005.450.
[112]中华医学会.临床诊疗指南·肿瘤分册[M].第1版.北京：人民卫生出版社,2005.
[113]Report a WHO Expert Committee. Cancer Pain Relief and Palliative Care. Geneva, 1996.
[114]Ada Jacox, etal. Clinical practice guideline NO.9. Management of Pain. US Department of health and Human Services, Public Heaths Agency for Heath Care Policy and Research [J]. AHCPR Publie 1994,94:592
[115]黄秀芳,许金森.足三里穴位注射疗法对恶性肿瘤患者外周血象变化的临床观察[J].中华现代中西医杂志,2004,2(3)：202.
[116]蔡欣然,黄长玉,周浩辉,等.HBV感染肝癌患者血清HBV-DNA水平与手术近期疗效的关系[J].肝胆外科杂志,2007,15(3)：175-177.
[117]王关林,那杰,潘凌子,等. 蜂毒肽抑杀病原菌的超微结构观察[J]. 中国科学C辑：生命科学,2009(5)：512-517.
[118]刘利波,杨静茹.乙型肝炎病毒感染与原发性肝癌研究进展[J].现代中西医结合杂志,2010，19(36)：4782-4784.
[119]Chu CM,Liaw YF. J Clin Pathol 1993,46:1004.
[120]Park J H, Jeong Y J, Park K K, et al. Melittin suppresses PMA-in-duced tumor cell invasion by inhibiting NF-kB and AP-1-Depend-ent MMP-9 Expression [J]. Mol Cell, 2010(2):209-215.
[121]倪志权,张保.中晚期肝癌疼痛的临床分析与综合治疗.河南肿瘤学杂志,1995,(3)：205-207.
[122]杨毓麟,姚朱姮,俞宗耀,等.蜂毒的镇痛作用一与吗啡、安替比林的比较[J].中国养蜂,1984(2)：26-27.
[123]王本祥.蜂毒的药理及临床应用[J].药学通报,1980,15(5)：24.
[124]陈郴永,陈维辛,孙欣.蜂毒蜂肽抗炎镇痛反应原性与急性毒性比较[J].中国中西医结合杂志,1993,(4)：226.
[125]马辉,常卫柱.联合应用硫酸吗啡控释片及蜂毒注射液控制癌痛的临床观察[J].吉林医学,2008,29(21)：1914-1915.
[126]秦敏,李利东.穴位敷贴肝俞、肾俞治疗中风恢复期20例疗效观察[J].针灸临床杂志,2007,23(7)：54-55.
[127]丁习益.肝俞穴临床应用[J].针灸临床杂志,2000,16(1)：34-36.
[128]韩秀华,王元敏,宋少军,等.艾灸肝俞、期门穴治疗慢性乙型肝炎的临床研究[J].中国现代医生,2011,49(19)：86-88.
[129]王守才,边作歧,郭书堂.胆俞穴按摩治疗胆绞痛186例[J].中国中医急症,1995,4(1)：14.
[130]张金森,焦玉林,邵风华.针刺胆俞穴为主治疗血管性头痛79例疗效分析[J].中国中医药信息杂志,1999,6(5)：76.
[131]唐照亮,章复清.艾灸对实验性炎症大鼠血清SOD活性和MDA含量的影响[J].安徽中医学院学报,1998；17(5)：44.
[132]廖方正,李利,廖品东.针刺肾俞对红细胞免疫功能的调节作用[J].中国针灸,1998,18(2)：75-76.
[133]国兰琴,陈汉平,吴焕淦,等.肾俞穴延缓衰老的应用与研究[J].辽宁中医杂志,2007,34(6)：732-734.
[134]程绍鲁,陈权彰,刘惠娟.远红外穴位照射缓解放疗或化疗对血象损害的观察[J].针灸临床杂志,2000,16(1)：37-38.
[135]张伯顺.水针治疗对慢性肝炎血清肝纤维化指标的影响[J].针灸临床杂志,1997,13(8)：231.
[136]崔瑾,申定珠,熊芳丽.针灸膈俞对白细胞共同抗原及免疫功能的影响[J].四川中医,2006,24(2)：100-102.
[137]雷海燕.足三里化脓灸对恶性肿瘤患者血象的影响[J].辽宁中医药大学学报,2010,12(1)：156-157.
[138]陈德成,吴旭,吴文忠,等.穴位注射对慢性萎缩性胃炎患者免疫调节作用机理研究[J].中国针灸,1998,18(2)：69.
[139]Kim HW, Kwon YB, Ham TW, et al. Acupoint Stimulation Using Bee Venom Attenuates Formalin — Induced Pain Behavior and Spinal Cord Fos Expression in Rats. The Journal of Veterinary Medical Science.2003,65(3):349-355.
[140]李万瑶,段颖华,李珊芸.蜂针严重过敏反应及防治的探讨[J].中国蜂业,2009,60(9)：37-39.
[2]赵永飞,王贵吉,裴迎新,等.肝癌患者生活方式与饮食危险因素调查河南医学研究,2012,21(4)：471-474.
[3]王清云肝癌与情志关系[J].吉林中医药,2004,24(8)：47
[4]胡学军,龙顺钦,杨小兵,等.原发性肝癌的中医体质调查分析[J].时珍国医国药,2010,21(4)：995-996.
[5]侯炜,梁婷,周雍明.原发性肝癌的中医药临床研究进展[J].肿瘤学杂志,2010,16(7)：534-536.
[6]孙秉严.癌症的治疗与预防[M].北京：春秋出版社,1988：3.
[7]刘亚娴.中西医结合肿瘤病学[M].北京：中国中医药出版社,2005.
[8]杨通礼.中医药治疗肝癌基本原则和方药初探[J].中国中医药导报,1996,11(6)：42-45.
[9]王天保,范言磊.辨证施治原发性肝癌153例[J].中医研究,1999,12(6)：46～47.
[10]张尚忠.对肝癌辨证施治的认识[J].山东中医学院学报,1978,(增刊)：178～179.
[11]韩克起,邱根全,孙喜才.肝癌发热证治六法[J].陕西中医,1996,17(7)：307-308.
[12]周维顺,谢长生.略论肝癌的诊治原则[J].浙江中医学院学报,1993,17(6)：4-5.
[13]谭开基,陈锐深.岭南肝癌的发病特点及辨证施治[J].新中医,1999,31(8)：25.
[14]刘庆,张彦博,马传红,等.原发性肝癌的中医治法与方药[J].中西医结合学报,2005,3(4)：260-262.
[15]高晓红.辨证治疗原发性肝癌28例[J].湖南中医杂志,2002,18(5)：27.
[16]陈洪国,杜晓军.内外合治中晚期肝癌30例山西中医,2005,21(5)：15.
[17]黄金昶,崔慧娟,王立森,等.养阴活血、温阳利水法为主治疗门静脉癌栓10例[J].中日友好医院学报,2005,19(2)：111-112.
[18]邵世祥,王子鑫,毕磊.五倍子散配合华蟾素注射液治疗原发性肝癌51例[J].实用中医内科杂志,2006,20(1)：93.
[19]田菲,贾英杰,陈军,等.温针灸对于恶性肿瘤患者的免疫微生物调控[J].针灸临床杂志,1999,15(5)：48-50.
[20]刘宏.针灸与穴位注射药物治疗肝癌疼痛疗效研究[J].河北中医药学报,2010,25(3)：37.
[21]刘立公,顾杰.癥瘕积聚的古代针灸治疗特点分析[J].针灸临床杂志,2004；20(2)：57.
[22]何秀兰,乔占兵,李忠.中医治肝癌评述[J].光明中医,2002；17(4)：37-39.
[23]丁正荣,李荣成,黄果勇,等.原发性肝癌与乙型肝炎病毒病因关系的流行病学分析与探讨
[J].中华流行病学杂志,1984,5(6)：146-149.
[24]丁正荣,李荣成,龚健,等.肝癌高发区HBsAg携带者及肝脏损害者发生肝癌的前瞻性研究[J].肝炎防治研究,1985,6(4)：22-30.
[25]Hsieh YH, SU IJ, Wang HC, et al. Pre-s mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage [J]. Carcinogenesis,2004,25 (10):2023.
[26]向光明,钟森,赵川,等.HBV相关肝细胞癌患者HBV前S／S基因变异的分析[J].泸州医学院学报,2006,29(5)：410-413.
[27]Wang XW, Forrester K, Yeh H, et al. Hepatitis B virus X protein inhibits p53 sequence-specific DNAbinding, transcriptional activity, and association with transcription factor ERCC3 (J). Proc Natl Acad Sci USA,1994,91:2230-2234.
[28]Webber EM,Wu JC, Wang L, et al. Overexpression of transforming growth factor-alphacauses liver enlargement and increased hepatocyte proliferation in transgenic mice (J). AmJ Pathol,1994,145:398-408.
[29]BATTAGLIA S, BENZOUBIR N, NOBILET S, et al. Liver cancer-derived hepatitis C virus core proteins shift TGF-β responses from tumor suppression to epithelial-mesenchymal transition[J]. PLoS One,2009,4:e4355.
[30]曾蓉,李秀玲,余蓉.蛇毒抗肿瘤作用研究进展[J].生物技术通讯,2002；13(6)：479-483.
[31]Simmonds P. Variability of hepatitis C virus [J]. Hepatology 1995,21(2):570—583.
[32]Gramantieri L, Trere D, Pession A, et al. Allelic imbalance on 16q in small, unifocal hepatocellular carcinoma:correlation with HBV and HCV infections and cellular proliferation rate[J].Dig, Dis Sci,2000,45(2):306—311.
[33]Tornillo L, Carafa V, Richter J, et al. Marked genetic Similari-ties between hepatitis B virus-positive and hepatitis C virus-positive hepatocellular carcinomas [J]. J Pathol, 2000,192(3):307-312.
[34]Ogata S, Ku Y, Yoon S, et,al.Correlation between secondary structure of an amino-terminal portion of the nonstructural protein 3 (NS3) of hepatitis C virus and development of hepa-tocellular carcinoma[J]. Microbiol Immunol,2002,46(8):549-554.
[35]Ray RB, Steele R, Meyer K, et al.J Bio Chem,1997; 272(17):10983-10986
[36]张文萍.蝎毒抗癌多肽的研究进展[J].中草药,2002；33(12)：1143-1145.
[37]李艳荣,刘云鹏.蟾蜍毒素的抗肿瘤作用.国外医学中医中药分册[J],2002；24(3)：152-155.
[38]陆再英,钟南山.内科学[M]. 北京：人民卫生出版社,2008：457-462.
[39]Lencioni R, Bartolozzi C, Caramella D, et al. Treatment of small hepatocellular carcinoma with percutaneous ethanol injection-analysis of prognostic factors in 105 western patients. Cancer,1995,76:1737.
[40]蔡鹏,孙劲松,杨士勇.全身γ刀治疗52例原发性肝癌近期疗效观察.中国肿瘤临床与康复,2002,9(5)：97.
[41]Sakon M, Nagano H, Dono K, et al. Combined intraarial 5—fluorouracil and subcutaneous interferon — alphatherapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer,2000,94:435—442.
[42]FENNELL JF, SHIPMAN WH, COLE LJ. Antibacterial action of a bee venom fraction (melittin) against a penicillin-resistant staphylococcus and other microorganisms[J]. Res Dev Tech Rep,1967:1-13.
[43]刘红云,童富淡. 蜂毒的研究进展及其临床应用[J]. 中药材,2003,26(6)：456-458.
[44]彭辉,张志芳. 蜂针联合三阶梯止痛疗法治疗癌痛的临床观察[J].湖南中医药大学学报,2010,30(9)：222-225.
[45]杨毓麟,姚珠姮,俞宗耀,等.蜂毒的镇痛作用——与吗啡、安替比林的比较[J].中国养 蜂,1984,(2)：26-27.
[46]Kubo H, Loegering DA, Adolphson CR, et al. Cytotoxic properties of eosinophil granule major basic protein for tumor cells [J]. Int Arch Allergy Immunol,1999; 118(2-4):426-428.
[47]Saini S S, Chopra A K, Peterson JW. Melittin activates endogenous phospholipase D during cytolysis of human monocytic leukemia cells[J]. Toxicon,1999,37(11):1605.
[48]张晨,凌昌全,李柏,等.蜂毒素对肝癌细胞系SMMC7721增殖的影响[J].中草药,2003,34(1)：43-45.
[49]KuboH, LoegeringD A, Adolphson C R, et a.1 Cytotoxic properties of eosinophil granulemajorbasic protein for tumor cells[J]. IntArch A-llergy Immuno,11999,118(2-4): 426.
[50]LazarevV N, Parfenova TM, Gularyan SK, et a.1 Induced expression of melittin, an antimicrobial peptide, inhibits infection by Chlamydia tra-chomatis andMycoplasma hominis in aHela cell line[J]. IntJAntim-icrob Agents,2002,19(2):133.
[51]Werkmeister JA, Kirkpatrick A, McKenzie JA, et al. The effect of sequence variations and structure on the cytolytic activity of melittin peptides[J]. Biochim Biophys Acta,1993,1157(1):50.
[52]Dunn RD,Weston KM, Longhurst TJ,et al. Antigen binding and cytotoxic properties of a recombinant immunotoxin incorpo-rating the lytic peptide[J]. Melittin Immunotechnology,1996,2(3):229.
[53]李爱剑,梁枫.蜂毒素对人胃癌细胞BGC823生长抑制作用的实验研究[J].中国中医急症,2009,18(5)：780.
[54]Harada M, Kimura G, Nomoto K. Heat shock proteins and the antitumor T cell response[J]. Biotherapy,1998,10 (3):229.
[55]王秋波,鲁迎年,臧云娟,等，蜂毒的免疫调节机制研究[J].中国免疫学杂志,2000,16(10)：542-544.
[56]高连臣.蜂毒对T淋巴细胞亚群的影响[J].养蜂科技,2004,23(3)：29-30.
[57]朱萱萱,王居祥,王瑞平,等.蜂毒对S180肉瘤鼠的免疫调节作用[J].中药药理与临床,2000,16(6)：24-25.
[58]黄雪强,凌昌全,陈哲,等.蜂毒素诱导人T淋巴细胞白血病细胞株6T-CEM的凋亡作用[J].安徽中医学院学报,2001；20(5)：39-41.
[59]Williams GT, Smith CA. Molecular regulation of apoptosis:genetic controls on cell death. Cell,1993,74 (5):777.
[60]周语平,杨志军,陈彻.细胞凋亡与肿瘤[J].甘肃中医学院学报,2003,20(4)：48-51.
[61]李玉梅,陈永强,顾伟.蜂毒及其主要成分蜂毒素抗肿瘤机制研究进展[J].中国中医药信息杂志,2008,15(1)：96-97.
[62]张晨,李柏,吕书勤,等.蜂毒素对人肝癌细胞线粒体膜蛋白7A6和凋亡相关基因产物Fas及其配体FasL表达的影响.中西医结合学报,2007,5(5)：559.
[63]Jang MH, Shin MC, Lim S, et al. Bee venom induces apoptosis and inhibits expression of cyclooxygenase-2 mRNA in human lung cancer cell line NCI-H1299[J]. J Parmacol Sci,2003,91: 95-104.
[64]Hwang DY, Kim HH, Kim CJ, et al. Bee venom induces apoptosis and inhibits COX-2 in human osteosarcoma cell line MG-63[J]. J Kor Acup Mox Soc,2003,20(3):63—74.
[65]Ahn CB, Im CW, Kim CH, et al. Apoptotic cell death by melittin through induction of Bax and activation of caspase proteases in human lung carcinoma cells[J]. J Kor Acup Mox Soc,2004,21(2):41-55.
[66]吴围屏,刘自元,孟令,等.蜂毒体外抗凝和降粘作用初探蜜蜂杂志,1999,(6)：3-4.
[67]徐彭,欧阳永伟,肖诚.蜂毒活血化痪作用的实验观察[J].中草药,1996,27(9)：542-543.
[68]游育红,邬大元,黄自强.蜂毒素对大鼠血小板内钙浓度的影响[J].福建医学院学报,1995,29(4)：347-348.
[69]陈远聪,袁士龙.毒素的研究和利用[M].科学出版社,1988年第1版：128-144.
[70]郭芳彬.蜂毒的现代药理研究[J].养蜂科技,2003,(2)：29-31.
[71]李惠敏,张苏刚,魏振满,等.复方蜂毒注射液对大鼠实验性肝纤维化的治疗作用[J].中国生化药物杂志,1998,19(1)：25-26.
[72]马爱生.以毒攻毒德研究用蜂毒对付艾滋病[J].蜜蜂杂志,2000,(2)：30.
[73]王强,王庆友.病毒性肝炎蜂毒抗病毒疗效分析[J].蜜蜂杂志,2003,9：4-5.
[74]张秀兰.蜂毒注射液治疗白塞病[J].中华皮肤科杂志,1997,30(1)：55.
[75]Chen J, et allThe contribution of spinal neuronal changes to development of prolonged, tonic nociceptive responese of the cat induced by subcutaneous bee venom injectionl Eur J Pain,1998,2 (4):359.
[76]Luo C, et allSpatial and temporal expression of c-Pos protein in the spinal cord of anesthetized rat induced by subcutaneous bee venom injectionlBrain Res, 1998,806 (2):175.
[77]李万瑶,涂成文,黄胜光.蜂针对类风湿性关节炎作用机理的研究[J].广东省针灸学会第十次学术交流会论文汇编[C].广东广州,2007.
[78]韩巧菊,于丽华,陈淑兰,等.蜂针、蜡疗及蜂产品和中药内服治疗早、中期强直性脊柱炎240例临床观察[J].河北中医,2010,32(8)：1213-1214.
[79]朱辉军,黄胜光,谭宁,等.蜂针合补肾化瘀方治疗强直性脊柱炎56例[J].中医药导报,2009，15(9)：33-34.
[80]王小寅.蜂针联合推拿治疗神经根型颈椎病50例疗效分析[J].中医临床杂志,2012,4(6)：44-45.
[81]沈明安.蜂针配合推拿治疗肩周炎临床观察[J].四川中医,2008,26(4)：117-118.
[82]黄海振,陈希,张还添,等.蜂针配合中药内服治疗膝骨性关节炎[J].光明中医,2008,23(9)：1273-1274.
[83]臧云娟, 王秋波,于海青,等.独穴蜂针疗法对变应性鼻炎防治效果的观察与分析[J].蜜蜂杂志,1999,(7)：3-4.
[84]文洁珍.蜂针治疗儿童哮喘的临床疗效及对免疫功能的影响[J].新中医,2006,38(7)：37-38.
[85]成永明,任小红,富永谦,等.蜂疗防治小儿反复呼吸道感染的临床研究[J].中医药导报,2005,11(9)：10-11.
[86]王太发.蜂针针刺穴位治疗面神经麻痹38例疗效观察光明中医,2010,25(4)：650.
[87]唐金贤,李素英.蜂针治疗96例原发性三叉神经痛[J].养蜂科技,1995,(3)：21-22.
[88]谭保华,王苏娜.蜂针蜇刺法治疗顽固性面瘫36例疗效观察[J].云南中医中药杂志,2012,33(1)：50.
[89]韩励兵,王苏娜,段晓荣,等.蜂针治疗脑梗塞50例疗效观察[J].云南中医中药杂志,2011,32(3)：43.
[90]陈景秀.超量蜂针治疗格林-巴利综合征7例[J].养蜂科技,2004,(3)：31-33.
[91]廖子俊,朱万云.足三里穴在蜂针治疗消化系统病症中的应用[J].中国蜂业,2009,60(6)：37-38.
[92]苏和祖,聂承和,陈玉钦.蜂针疗法治疗肝硬化32例疗效观察[J].蜜蜂杂志,1994,(9)：5-7.
[93]代乾.蜂胶酊中药合剂与蜂针综合治疗慢性喉炎[J].中国蜂业,2011,62(4)：34.
[94]朱金明.蜂疗为何能帮助阑尾炎患者保留阑尾[J].2006,(6)：26-28.
[95]成永明,任小红,余伯亮.蜂疗治疗小儿遗尿症60例[J].实用医学杂志,2009,25(16)：2777.
[96]周福环,周福锁.蜂针配合毫针治疗乳腺增生127例临床观察[J].中国养蜂,2005,56(2)：28.
[97]吴新新.蜂针治疗功能性痛经10例[J].蜜蜂杂志,2006,(2)：32.
[98]代乾.地归敷贴与蜂针治疗更年期综合症[J].中国蜂业,2008,59(5)：33.
[99]廖子俊,朱万云.慢性前列腺炎的临床症状及蜂针疗法[J].中国蜂业,2009,60(1)：36-37.
[100]廖子俊,朱万云.痤疮蜂针疗法[J].中国蜂业,2009,60(12)：42-43.
[101]代乾.蜂针和复方蜂胶液治疗湿疹104例效果分析[J].养蜂科技,2004(3)：34-35.
[102]石桂华,郑建寅,罗铁阳.蜂针配合矿泉浴治疗关节型银屑病[J].中华皮肤科杂志,1997，30(5)：346-347.
[103]廖子俊,朱万云.银屑病的临床症状及蜂针疗法[J].中国蜂业,2009,60(5)：31-32.
[104]耿振方,马中梅.蜂针治愈体表血管瘤、皮肤纤维瘤85例[J].养蜂科技,2004,(6)：30.
[105]葛来安,彭莉莉,杨保东.蜂针联合中药治疗晚期肝癌的临床体会[J].江西中医药,2009，40(11)：36-37.
[106]王居祥,朱超林,王瑞平,等.蜂毒注射液治疗恶性肿瘤的临床观察[J].南京中医药大学学报,2006,22(3)：157-159.
[107]彭莉莉,葛来安,严景妍,等.中药联合蜂针辨证治疗慢性乙型肝炎50例临床观察[J].辽宁中医杂志,2010,37(12)：2373-2375.
[108]刘文清,吴汉周.蜂毒治疗慢性乙型肝炎与肝硬化32例[J].中西医结合肝病杂志,1993,3,(4)：31-32.
[109]杨文超,戴荣国,吴珍红,等.蜂毒肽抗HSV-1病毒作用的机理研究[J].中国蜂业,2010,61(12)： 35-36.
[110]陈世云,熊俊,李万瑶.近30年蜂针疗法病症谱的文献研究[J].广州中医药大学学报,2012,29(6)：733-735.
[111]刘厚钰.原发性肝癌[M].北京：人民卫生出版社,2005.450.
[112]中华医学会.临床诊疗指南·肿瘤分册[M].第1版.北京：人民卫生出版社,2005.
[113]Report a WHO Expert Committee. Cancer Pain Relief and Palliative Care. Geneva, 1996.
[114]Ada Jacox, etal. Clinical practice guideline NO.9. Management of Pain. US Department of health and Human Services, Public Heaths Agency for Heath Care Policy and Research [J]. AHCPR Publie 1994,94:592
[115]黄秀芳,许金森.足三里穴位注射疗法对恶性肿瘤患者外周血象变化的临床观察[J].中华现代中西医杂志,2004,2(3)：202.
[116]蔡欣然,黄长玉,周浩辉,等.HBV感染肝癌患者血清HBV-DNA水平与手术近期疗效的关系[J].肝胆外科杂志,2007,15(3)：175-177.
[117]王关林,那杰,潘凌子,等. 蜂毒肽抑杀病原菌的超微结构观察[J]. 中国科学C辑：生命科学,2009(5)：512-517.
[118]刘利波,杨静茹.乙型肝炎病毒感染与原发性肝癌研究进展[J].现代中西医结合杂志,2010，19(36)：4782-4784.
[119]Chu CM,Liaw YF. J Clin Pathol 1993,46:1004.
[120]Park J H, Jeong Y J, Park K K, et al. Melittin suppresses PMA-in-duced tumor cell invasion by inhibiting NF-kB and AP-1-Depend-ent MMP-9 Expression [J]. Mol Cell, 2010(2):209-215.
[121]倪志权,张保.中晚期肝癌疼痛的临床分析与综合治疗.河南肿瘤学杂志,1995,(3)：205-207.
[122]杨毓麟,姚朱姮,俞宗耀,等.蜂毒的镇痛作用一与吗啡、安替比林的比较[J].中国养蜂,1984(2)：26-27.
[123]王本祥.蜂毒的药理及临床应用[J].药学通报,1980,15(5)：24.
[124]陈郴永,陈维辛,孙欣.蜂毒蜂肽抗炎镇痛反应原性与急性毒性比较[J].中国中西医结合杂志,1993,(4)：226.
[125]马辉,常卫柱.联合应用硫酸吗啡控释片及蜂毒注射液控制癌痛的临床观察[J].吉林医学,2008,29(21)：1914-1915.
[126]秦敏,李利东.穴位敷贴肝俞、肾俞治疗中风恢复期20例疗效观察[J].针灸临床杂志,2007,23(7)：54-55.
[127]丁习益.肝俞穴临床应用[J].针灸临床杂志,2000,16(1)：34-36.
[128]韩秀华,王元敏,宋少军,等.艾灸肝俞、期门穴治疗慢性乙型肝炎的临床研究[J].中国现代医生,2011,49(19)：86-88.
[129]王守才,边作歧,郭书堂.胆俞穴按摩治疗胆绞痛186例[J].中国中医急症,1995,4(1)：14.
[130]张金森,焦玉林,邵风华.针刺胆俞穴为主治疗血管性头痛79例疗效分析[J].中国中医药信息杂志,1999,6(5)：76.
[131]唐照亮,章复清.艾灸对实验性炎症大鼠血清SOD活性和MDA含量的影响[J].安徽中医学院学报,1998；17(5)：44.
[132]廖方正,李利,廖品东.针刺肾俞对红细胞免疫功能的调节作用[J].中国针灸,1998,18(2)：75-76.
[133]国兰琴,陈汉平,吴焕淦,等.肾俞穴延缓衰老的应用与研究[J].辽宁中医杂志,2007,34(6)：732-734.
[134]程绍鲁,陈权彰,刘惠娟.远红外穴位照射缓解放疗或化疗对血象损害的观察[J].针灸临床杂志,2000,16(1)：37-38.
[135]张伯顺.水针治疗对慢性肝炎血清肝纤维化指标的影响[J].针灸临床杂志,1997,13(8)：231.
[136]崔瑾,申定珠,熊芳丽.针灸膈俞对白细胞共同抗原及免疫功能的影响[J].四川中医,2006,24(2)：100-102.
[137]雷海燕.足三里化脓灸对恶性肿瘤患者血象的影响[J].辽宁中医药大学学报,2010,12(1)：156-157.
[138]陈德成,吴旭,吴文忠,等.穴位注射对慢性萎缩性胃炎患者免疫调节作用机理研究[J].中国针灸,1998,18(2)：69.
[139]Kim HW, Kwon YB, Ham TW, et al. Acupoint Stimulation Using Bee Venom Attenuates Formalin — Induced Pain Behavior and Spinal Cord Fos Expression in Rats. The Journal of Veterinary Medical Science.2003,65(3):349-355.
[140]李万瑶,段颖华,李珊芸.蜂针严重过敏反应及防治的探讨[J].中国蜂业,2009,60(9)：37-39.